Co-Diagnostics, Inc. Announces Sales of New Coronavirus Test
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: Business Wire
SALT LAKE CITY--(BUSINESS WIRE)--Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today sales of its screening test designed to identify the presence of the novel coronavirus that originated in China before spreading across the world over the past month. The order calls for delivery of tests to be distributed to various international markets and included payment for the initial shipment of assays.Co-Diagnostics Logix Smart™ 2019-nCoV polymerase chain reaction (PCR) tests use highly specific targeting and the Company’s patented CoPrimer™ technology platform to detect the strain of coronavirus first discovered in the Chinese city of Wuhan on December 31, 2019. The test is compatible with various manufacturers’ PCR devices that are commonly used, and is immediately available on a Research Use Only (RUO) basis to thousands of laboratories throughout the world.Dwight Egan, Co-Diagnos
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Global COVID-19 Diagnostic Market Report 2024 -2029: A New Very Large and Sustainable Market for Covid Related Diagnostics is Emerging [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo FacilityPR Newswire
- Co-Diagnostics, Inc. (NASDAQ: CODX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CODX
Earnings
- 11/7/24 - Beat
CODX
Analyst Actions
- 11/11/24 - HC Wainwright
CODX
Sec Filings
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- CODX's page on the SEC website